𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma

✍ Scribed by Richard Pazdur; Jaffer J. Ajani; James L. Abbruzzese; Robert J. Belt; Shaker R. Dakhil; Daniel Dubovsky; Suzanne Graham; Susan Pilat; Rodger Winn; Bernard Levin

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
421 KB
Volume
70
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of 5-fluorouracil and r
A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma
✍ Richard Pazdur; Jaffer A. Ajani; Rodger Winn; James Bearden; Robert J. Belt; Sus 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 1 views

A Phase I1 clinical trial of the combination of 5-fluorouracil (5-FU) and recombinant alpha-2a-interferon (a-2a-IFN) was conducted in 44 patients. Patients had not received chemotherapy previously and had measurable metastatic gastric carcinoma. 5-FU was administered as a continuous infusion at a do

5-fluorouracil and low-dose recombinant
5-fluorouracil and low-dose recombinant interferon-α-2a in patients with hormone-refractory adenocarcinoma of the prostate
✍ Shinohara, Nobuo; Demura, Takayoshi; Matsumura, Kin-ya; Toyoda, Ken-ichi; Kashiw 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 1 views

## Background: The effectiveness of a chemotherapy regimen including 5-fluorouracil (5-fu) and recombinant interferon-alpha-2a (rifn-alpha-2a) was evaluated in hormone-refractory prostate cancer patients. ## Methods: Patients received a continuous intravenous infusion of 5-fu at 600 mg/m2/day for